Skip to main content

Table 1 Clinical and Pathological features of ovarian cancer patients according to deleterious BRCA1/2 mutations

From: Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil

 

BRCA 1/2 mut

BRCA1/2 wt

n = 19

n = 81

Age at diagnosis, median (range), years

54 (39–63)

55 (33–81)

Time between diagnosis and inclusion (months)

23.33 ± 14.53

19.83 ± 13.52

Histology, n (%)

 Serous

18 (94.7)

66 (81.5)

 Non-serous

1 (5.3)

15 (18.5)

Clinical Stage, n (%)

 I/II

0 (0)

21 (25.9)

 III/IV

19 (100)

59 (72.8)

 Missing

0 (0)

1 (1.2)

Region of origin, n (%)

 Southeast

9 (47.4)

48 (59.3)

 Northeast

7 (36.8)

21 (25.9)

 South

2 (10.5)

8 (9.9)

 North

1 (5.3)

1 (1.2)

 Abroad

0 (0)

2 (2.4)

 Missing

0 (0)

1 (1.2)

Ancestry until 3rd degree, n (%)

 Brazilian only

7 (36.8)

31 (38.3)

 European only

2 (10.5)

12 (14.8)

 Japanese only

1 (5.3)

4 (4.9)

 Asian only

0 (0)

1 (1.2)

 Brazilian and European

5 (26.3)

16 (19.8)

 Brazilian and Indigenous

2 (10.5)

1 (1.2)

 Indigenous and European

0 (0)

1 (1.2)

 Indigenous and Brazilian and European

2 (10.5)

1 (1.2)

 Brazilian and African

0 (0)

2 (2.5)

 Brazilian and African and European

0 (0)

1 (1.2)

 Brazilian and Japanese

0 (0)

2 (2.5)

 Unknown

0 (0)

8 (9.9)

 Missing

0 (0)

1 (1.2)

Family history for breast and/or ovarian cancer

 Positive (first and/or second-degree relatives)

11 (57.9)

20 (24.7)

 Negative

5 (26.3)

32 (39.5)

 Not Completely Known/Unknown

3(15.8)

29 (35.8)